• By inhibiting PRMT3 activity, SGC707 reduces hepatic triglyceride accumulation and lowers plasma triglyceride levels, thereby ameliorating hepatic steatosis and dyslipidemia. This evidence concerns the gene PRMT3 and fatty liver disease.